Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRII-835 and PEG-IFNα in Chronic Hepatitis B
NCT05970289Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
A Phase 2 trial of elebsiran in chronic hepatitis B virus infection (CHB), sponsored by Brii Biosciences. Started Aug 2023; status: completed.
02
Drugs
elebsiran
03
Conditions
chronic hepatitis B virus infection (CHB)
Beyond the preview
Go deeper on NCT05970289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970289.